Grand Mal Seizure Treatment Global Market Report 2023 – By Type (Barbiturates, Hydantoin, Phenyltriazine, Iminostilbenes, Benzodiazepines, Aliphatic Carboxylic Acids, Other Types), By Diagnosis (Magnetic Resonance Imaging (MRI), Electroencephalogram (EEG), Blood Tests, Computed Tomography (CT), Other Diagnosis), By Treatment (Antiepileptic Drugs, Surgery, Vagus Nerve Stimulation, Ketogenic Diet, Other Treatments), By End Users (Academic And Research Centers, Neurological Centers, Hospitals, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

Generic central nervous system (CNS) drugs refer to the drugs that have an impact on the central nervous system agents (CNS) by slowing down brain activity. They are used to treat seizures, anxiety, panic attacks, and insomnia. The major classes of generic central nervous system drugs are immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, and analgesics. Immunomodulatory medicines refer to the medicines that stimulate or suppress the formation of serum antibodies, alter how the immune system reacts to an antigen. These drugs are used to cure major diseases, such as neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, and CNS cancer. These drugs can be administered through oral and parenteral. They are sold through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. The global generic central nervous system drugs market is segmented - 1) By Drug Class: Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, Analgesic 2) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer 3) By Route Of Administration: Oral, Parenteral 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global generic central nervous system drugs market size is expected to grow from $77.47 billion in 2022 to $82.45 billion in 2023 at a compound annual growth rate (CAGR) of 6.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global generic central nervous system drugs market size is expected to grow to $103.95 billion in 2027 at a CAGR of 6.0%. The increasing prevalence of central nervous system (CNS) disorders is expected to propel the growth of the generic central nervous system drugs market going forward. Disorders of the central nervous system include infections such as meningitis, encephalitis, polio, bell's palsy, cervical spondylosis and others. Generic central nervous system drugs are used to treat these diseases, hence increasing prevalence of disorders will drive the generic central nervous system drugs market. For instance, according to Global Cancer Statistics 2020 published by ACS Journals, a journal of US-based American Cancer Society, 308,102 new cases of brain and CNS cancers were diagnosed, and 251,329 cancer-related deaths occurred in 2020 worldwide. Thus, the increasing prevalence of central nervous system (CNS) disorders will drive the growth of the generic central nervous system drugs market. Major players in the generic central nervous system drugs market are Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Merck & Co., Astra Zeneca, Shire PLC., Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., AbbVie Inc., Alkermes PLC., Allergan PLC., Bristol-Myers Squibb, Eisai Co. Ltd., Endo Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC., H. Lundbeck A/S, Janssen Pharmaceuticals Inc., and Neurocrine Biosciences Inc. Product innovations have emerged as a key trend gaining popularity in the generic central nervous system drugs market. Major companies operating in the generic central nervous system drugs market are focused on developing innovative products and solutions to strengthen their position in the market. For instance, in March 2020, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, launched AJOVY, a humanized monoclonal antibody for the treatment of migraine in adults. AJOVY is the first and only anti-CGRP (anti-calcitonin gene-related peptide) treatment for the prevention of migraine, with monthly and quarterly dosing options. The company launched this drug product in the pre-filled YpsoMate 2.25 autoinjector from the firm called Ypsomed, a Switzerland-based developer and manufacturer of injection and infusion systems. In November 2022, Avenue Therapeutics, a US-based specialty pharmaceutical company, acquired Baergic Bio for an undisclosed amount. This acquisition makes Avenue a pioneer in the creation of medications that address unmet medical needs in the CNS field. Baergic Bio is a US-based biopharmaceutical company dedicated to the creation and marketing of cutting-edge therapies for the management of CNS (central nervous system) diseases. North America was the largest region in the generic central nervous system drugs market in 2022. The regions covered in the global generic central nervous system drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the generic central nervous system drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The generic central nervous system drugs market consists of sales of sedatives, tranquilizers, and hypnotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The generic central nervous system drugs market research report is one of a series of new reports from The Business Research Company that provides generic central nervous system drugs market statistics, including generic central nervous system drugs industry global market size, regional shares, competitors with a generic central nervous system drugs market share, detailed generic central nervous system drugs market segments, market trends and opportunities, and any further data you may need to thrive in the generic central nervous system drugs industry. This generic central nervous system drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Single-photon emission computed tomography (SPECT) is a medical imaging technique that uses radioactive tracers and gamma rays to produce 3D images of internal organs and tissues. The tracer can be detected by a gamma camera by emitting gamma rays, allowing for non-invasive and detailed imaging of a patient's internal structure. The main types of single-photon emission computed tomography (SPECT) systems are hybrid and standalone SPECT systems. Hybrid SPECT systems refer to a medical imaging device that combines functional and anatomical information obtained from SPECT and CT or MRI and provides more accurate diagnoses. Various radioisotopes involved in SPECT systems include Tc-99m, Ra-223, Ga-67, I-123, and other radioisotopes in a variety of applications such as oncology, cardiology, neurology, and other applications by hospitals, diagnostic centers, and other end users. The global single-photon emission computed tomography (SPECT) market is segmented - 1) By Type: Hybrid SPECT Systems, Standalone SPECT Systems 2) By Type Of Radioisotopes: Tc-99m, Ra-223, Ga-67, I-123, Other Radioisotopes 3) By Application: Oncology, Cardiology, Neurology, Other Applications 4) By End User: Hospitals, Diagnostic Centers, Other End User The global single-photon emission computed tomography (SPECT) market size is expected to grow from $2.13 billion in 2022 to $2.27 billion in 2023 at a compound annual growth rate (CAGR) of 6.75%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global single-photon emission computed tomography (SPECT) market size is expected to reach $3.04 billion in 2027 at a CAGR of 7.52%. The rise in the prevalence of cases of cancer is expected to propel the growth of the single-photon emission computed tomography (SPECT) market going forward. This rise in the number of cancer cases has resulted from a rise in the aging population, unhealthy lifestyle choices, and environmental factors. Single-photon emission computed tomography (SPECT) helps in the diagnosis, staging, and monitoring of cancer along with other imaging techniques like computed tomography (CT) and Magnetic Resonance Imaging (MRI) scans. For instance, in December 2020, according to a research article published by the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency and part of the World Health Organization, 19.3 million new cancer cases were reported and the number of deaths due to cancer accounted for 10 million in 2020. Female breast cancer is projected to be the most prevalent cancer globally, followed by lung, colorectal, prostate, and stomach cancers. Therefore, the rise in the prevalence of cases of cancer is driving the growth of the single-photon emission computed tomography (SPECT) market. Major players in the single-photon emission computed tomography (SPECT) market are GE HealthCare Technologies Inc., Siemens Healthineers, Bruker Corporation, Digirad Corporation, Mediso Ltd., DDD-Diagnostic A/S, Bracco Diagnostic Imaging, Cardinal Health Inc., Curium Pharma, Spectrum Dynamics Medical, Koninklijke Philips N.V., Beijing Hamamatsu Photon Techniques Inc., Novartis AG, MIE Medical Imaging Electronics GmbH and Global Medical Solutions Private Limited. Technological advancements are a key trend gaining popularity in the single-photon emission computed tomography (SPECT) market. Companies operating in the single-photon emission computed tomography (SPECT) market are adopting new technologies like high-resolution imaging to sustain their position in the market. For instance, in June 2022, Siemens Healthcare, a Germany-based medical device and medical solution manufacturing company, launched the Symbia Pro. Spectra SPECT/CT Scanner. This Symbia Pro. Spectra SPECT/CT device has advanced imaging technology, improved accessibility, optimal low-dose imaging, automated SPECT motion correction, and customized clinical tools designed for imaging in cardiology, oncology, orthopedics, and neurology applications. This device also has the myExam Companion feature, which enables automated workflow guidance. In November 2020, GE Healthcare, a US-based medical technology company, acquired Prismatic Sensors for an undisclosed amount. This acquisition will enable GE Healthcare to use deep silicon detector technology for photon counting computed tomography (PCCT) of prismatic sensors. This advanced technology will enable GE Healthcare to expand its clinical capabilities, achieve detailed visualization of organ structures, and improve tissue characterization. Prismatic Sensors is a Sweden-based start-up company specializing in photon-counting detector manufacturing. North America was the largest region in the single-photon emission computed tomography (SPECT) market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global single-photon emission computed tomography (SPECT) market report during the forecast period. The regions covered in the global single-photon emission computed tomography (SPECT) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the single-photon emission computed tomography (SPECT) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The single-photon emission computed tomography (SPECT) market consists of the sale of SPECT/CT and of Single Imaging Gamma Cameras. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The single-photon emission computed tomography (SPECT) market research report is one of a series of new reports from The Business Research Company that provides single-photon emission computed tomography (SPECT) market statistics, including global market size, regional shares, competitors with a single-photon emission computed tomography (SPECT) market share, detailed single-photon emission computed tomography (SPECT) market segments, market trends and opportunities, and any further data you may need to thrive in the single-photon emission computed tomography (SPECT) industry. This single-photon emission computed tomography (SPECT) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cone beam computed tomography (CBCT) refers to a technique in which a cone-shaped tomographic imaging beam is revolved around a patient's head to acquire focused pictures of a small area of the body, as in the case of dental scans. It is used for the treatment planning of orthodontics and dental implants. The main types of patient positions involved in cone beam computed tomography are standing, seated, and supine. The standing position in a cone-beam computed tomography (CBCT) scanner is a specific positioning of the patient during the imaging process. It is used in several applications, such as dental implantology, oral and maxillofacial surgery, orthodontics, endodontics, general dentistry, temporomandibular joint (TMJ) disorders, periodontics, forensic dentistry and others, and are used by several end-users, such as hospitals, dental clinics and others. The global cone beam computed tomography market is segmented - 1) By Patient Position: Standing, Seated, Supine 2) By Application: Dental Implantology, Oral And Maxillofacial Surgery, Orthodontics, Endodontics, General Dentistry, Temporomandibular Joint (TMJ) Disorders, Periodontics, Forensic Dentistry, Other Applications 3) By End User: Hospitals, Dental Clinics, Other End-Users The global cone beam computed tomography market size is expected to grow from $1.07 billion in 2022 to $1.21 billion in 2023 at a compound annual growth rate (CAGR) of 12.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cone beam computed tomography market size is expected to reach $1.88 billion in 2027 at a CAGR of 11.6%. The increasing cases of dental disorders are expected to propel the growth of the cone beam computed tomography market going forward. Dental disorders refer to the types of oral conditions that affect oral health, including gum disease, tooth erosion, and cavities. Dental disorders can be painful and uncomfortable, may limit one's capacity to eat, and may be detrimental to one's self-esteem. Cone beam computed tomography is primarily used to detect dental problems before they occur, which improves the endodontist's capacity to identify, assess, and care for patients as well as evaluate issues with the jaw, teeth, and skeletal aspects of the face. For instance, in March 2023, according to a report shared by the World Health Organization (WHO), a Switzerland-based health organization, globally, oral diseases affected almost 3.5 billion individuals. Approximately 10 percent of people worldwide have severe periodontal gum disease, which can result in tooth loss. Additionally, 2.3 billion individuals worldwide have dental caries in their permanent teeth, and 520 million children worldwide suffer from primary tooth decay. Therefore, the increasing cases of dental disorders are driving the growth of the cone-beam computed tomography market. Major players in the cone beam computed tomography market are Dentsply Sirona Inc., Planmeca Group, Vatech Co. Ltd., Asahi Roentgen Industry Co Ltd., Brainlab AG, CurveBeam AI, J. Morita Corporation, NewTom, PreXion Inc., Canon Medical Systems Corporation, Fussen Group, Gendex Dental systems, Genoray Co. Ltd., Idetec Medical Imaging, and Instrumentarium Dental Inc. Product innovations are a key trend gaining popularity in the cone beam computed tomography market. Major companies involved in the cone-beam computed tomography market are focused on innovating their products to improve their observation power and sustain their position in the market. For instance, in May 2021, PreXion Inc., a US-based medical equipment manufacturer, launched PreXion 3D Explorer PRO, a new version of the first 3D CBCT imaging equipment with an integrated cephalometric X-ray. This version of the device has a built-in cephalometric X-ray arm. The high-resolution cone-beam computed tomography (CBCT) scanner PreXion 3D Explorer PRO is utilized for dental and maxillofacial imaging. It makes use of cutting-edge 3D imaging technology to create extremely accurate and detailed photographs of the teeth, jaws, and facial structures, enabling better diagnosis and treatment planning. Additionally, key distinctive features also include an ingenious built-in ceph arm design that frees up more than two feet of space. Low dosage, HD, and endo CT modes, as well as 14-second pano and 16-second ceph scan timings, all have scan times of 20 seconds or less. In April 2022, Envista Holdings Corporation, a US-based dental equipment and supplies manufacturing company, acquired Carestream Dental's intraoral scanner business for an undisclosed amount. With this acquisition, Envista Holdings Corporation aims to expand its line-up of superior intraoral scanners and software, focus on the dental market's fastest-growing categories, and develop unique solutions through digitizing dental workflows. Carestream Dental is a US-based medical equipment manufacturing company that provides CBCT (cone beam computed tomography) systems and dental imaging systems. North America was the largest region in the cone beam computed tomography market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global cone beam computed tomography market during the forecast period. The regions covered in the global cone beam computed tomography market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cone-beam computed tomography market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cone-beam computed tomography market includes of revenues earned by entities by providing bone grafting evaluation, extraction of impacted wisdom teeth, and oral disease detection services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cone beam computed tomography market research report is one of a series of new reports from The Business Research Company that provides cone beam computed tomography market statistics, including cone beam computed tomography industry global market size, regional shares, competitors with a cone beam computed tomography market share, detailed cone beam computed tomography market segments, market trends and opportunities, and any further data you may need to thrive in the cone beam computed tomography industry. This cone beam computed tomography market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Computed tomography (CT) scanner devices and equipment are used in the diagnosis of various diseases including cancer, bone-related diseases, cardiovascular diseases, gynecological diseases, urological diseases, and other diseases. CT scanners use computer-controlled X-rays to create images of the body. The main product types in the computed tomography scanner devices and equipment are low slice, medium slice, and high slice. A higher slice CT produces higher resolution images and can produce an image of a heart in a single beat. The various applications involved are oncology, neurology, cardiovascular, musculoskeletal, and others. The end-users involved are clinics, diagnostic services, and hospitals. The global computed tomography (CT) scanners devices and equipment market is segmented - 1) By Product Type: Low Slice, Medium Slice, High Slice 2) By Application: Oncology, Neurology, Cardiovascular, Musculoskeletal, Other Applications 3) By End User: Clinics, Diagnostic Services, Hospitals The global computed tomography (CT) scanners devices and equipment market size will grow from $8.29 billion in 2022 to $8.63 billion in 2023 at a compound annual growth rate (CAGR) of 4.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global computed tomography (CT) scanners devices and equipment is expected to grow from $9.5 billion in 2027 at a CAGR of 2.5%. The rising prevalence of cancer and cardiovascular diseases is driving the computed tomography (CT) scanner devices and equipment market demand. According to the Centers for Disease Control and Prevention in the USA, the number of new cancer cases will increase by 24% in men and 21% in women by 2020. The rising need for early-stage detection and prevention of these life-threatening diseases increases the demand for proper diagnostics, which poses an opportunity for CT scan manufacturers. For instance, according to the American Heart Association; by 2035, 45.1% of the US population is projected to have some form of CVD. Total costs of CVD are expected to reach $1.1 trillion in 2035, with direct medical costs projected to reach $748.7 billion and indirect costs estimated to reach $368 billion. Major players in the computed tomography scanners devices and equipment market report are GE Healthcare, Koninklijke Philips N.V, Hitachi Ltd., Siemens, Canon Medical Systems Corporation, Neusoft Medical Systems, Hitachi Healthcare America, Neurologica, Samsung Electronics, and Shimadzu Corporation. Effects of radiation and increasing health concerns hinder the computed tomography (CT) scanner devices and equipment market growth. Diagnostic imaging procedures use CT scanner devices that release electromagnetic waves or particles called 'ionizing radiation. This radiation coming from manmade sources such as CT scans, nuclear medicine scans, and PET scans carry major health hazards and risks. Low doses can cause cancer in the long run. For instance, according to WHO data 2022, Cancer is a leading cause of death globally, accounting for nearly 10 million deaths in 2020. [ii]When doses exceed certain levels it causes skin burns and acute radiation syndrome. According to a global survey conducted by National Council on Radiation Protection and Measurements (NCRP), on radiation overexposure accidents, 2390 people were over-exposed to radiation, out of which 190 died. Companies in the computed tomography (CT) scanners devices and equipment industry are integrating medical imaging with healthcare IT technology by providing digital access to improve patient safety, enhance healthcare facilities and save patients time and money. The data from CT scans are being integrated with an image processing and communicating system such as a picture archiving and communication system (PACS) that brings CT images from multiple systems into one interface. This enables radiologists to securely store, and digitally transmit electronic images and clinically relevant reports, and make use of a comprehensive database of images to give an accurate diagnosis. These are increasingly incorporated and used for clinical analysis, diagnosis, and treatment in departments such as radiology, nuclear medicine imaging, cardiology, pathology, oncology, and dermatology. For example, Prismatic Sensors AB is a Swedish company developing photon counting detectors for computed tomography. An agreement has been signed by GE healthcare to acquire Prismatic Sensors AB in November 2020. North America was the largest region in the computed tomography scanners devices and equipment market in 2022. Western Europe was the second largest region in the global computed tomography (CT) scanners devices and equipment market share. The regions covered in the computed tomography (CT) scanners devices and equipment market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the computed tomography (CT) scanners devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The computed tomography (CT) scanner devices and equipment market consist of sales of low-end segment (single and dual slice CT scanners), mid-end segment (multi-slice scanners), and high-end slice segment (open versions, and cardiac CT scanners) that are used for CT scanning. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The computed tomography (CT) scanners devices and equipment market research report is one of a series of new reports from The Business Research Company that provides computed tomography (CT) scanners devices and equipment market statistics, including computed tomography (CT) scanners devices and equipment industry global market size, regional shares, competitors with computed tomography (CT) scanners devices and equipment market share, detailed computed tomography (CT) scanners devices and equipment market segments, computed tomography (CT) scanner devices and equipment market trends and opportunities, and any further data you may need to thrive in the computed tomography (CT) scanners devices and equipment industry. This computed tomography (CT) scanner devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Brain health supplements refer to supplements that improve brain function in healthy individuals. It also improves memory, motivation, creativity, attentiveness, and the overall cognitive performance of the brain. The main products of brain health supplements are natural molecules, herbal extracts, vitamins, and minerals. Natural molecules refer to complex molecules composed largely of carbon atoms linked to other elements and/or carbon atoms. These supplements are available in the form of tablets, capsules, and liquids, which are distributed by supermarkets and hypermarkets, drug stores, and online. It is used for various applications such as memory enhancement, mood and depression management, attention and focus, longevity and anti-aging, sleep and recovery, and anxiety management. The global brain health supplements market is segmented - 1) By Product: Natural Molecules, Herbal Extract, Vitamins, and Minerals 2) By Supplement Form: Tablets, Capsules, Liquid 3) By Distribution: Supermarket and Hypermarket, Drug Store, Online 4) By Application: Memory Enhancement, Mood and Depression, Attention and Focus, Longevity and Anti-Aging, Sleep and Recovery, Anxiety The global brain health supplements market size is expected to grow from $8.61 billion in 2022 to $9.60 billion in 2023, at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the brain health supplements market is expected to grow to $14.61 billion in 2027 at a CAGR of 11.1%. An increase in the prevalence of brain diseases is expected to propel the growth of the brain health supplements market going forward. Brain diseases refer to a disability that affects the brain and is considered a disorder. Essential nutrient supplementation, such as long-chain polyunsaturated fatty acids, vitamin E, and mineral elements, may reduce inflammation, improve antioxidative defense, and reduce the risk. For instance, in October 2022, according to a report released by the BrightFocus Foundation, a US-based non-profit organization, it is expected that about 500k new instances of Alzheimer's disease would be identified in the United States every year. Alzheimer's dementia affects 5% of those aged 65 to 74, 13% of those aged 75 to 84, and 33% of those aged 85 and older. Therefore, an increase in the prevalence of brain diseases is driving the growth of the brain health supplements market. Major players in the brain health supplements market are Accelerated Intelligence Inc., AlternaScript LLC, Aurobindo Pharma Limited (Natroll LLC), HVMN Inc., Intelligent Labs, KeyView Labs Inc., Liquid Health Inc., Natural Factors Nutritional Products Ltd., NOW Foods, Onnit Labs LLC, Peak Nootropics, Purelife Bioscience Co. Ltd., Quincy Bioscience LLC, Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Ltd., and Vital Basics Inc. Product innovation is a key trend gaining popularity in the brain health supplements market. Major companies operating in the brain health supplements market are developing innovative products to sustain their position in the brain health supplements market. For instance, in March 2022, Cosmos Holdings, a US-based pharmaceutical company, launched Proprietary Sky Premium Life Brainlit, an advanced formula to maintain and enhance brain function. Alzheimer's disease and other kinds of dementia, Parkinson's disease, depression, and anxiety have all been on the rise in recent years, despite a substantial unmet demand for effective treatment alternatives. The Brainlit supplement is created with the best quality raw ingredients and includes Ginkgo biloba, glutamine, L-tyrosine, and other vitamins and minerals important for brain function. In September 2021, HAVN Life Sciences, a Canada-based biotechnology company, acquired Bennett's Choice for an undisclosed amount. This acquisition adds a fresh and exceptional collection of patented formulas to our line of natural health products. Bennett's Choice is a Canada-based supplement development company. North America was the largest region in the brain health supplements market share in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brain health supplements market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the brain health supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The brain health supplements market consists of sales of B vitamins, caffeine, and L-theanine products. Values in this market are ‘nutraceuticals’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The brain health supplements market research report is one of a series of new reports from The Business Research Company that provides brain health supplements market statistics, including brain health supplements industry global market size, regional shares, competitors with a brain health supplements market share, detailed brain health supplements market segments, market trends and opportunities, and any further data you may need to thrive in the brain health supplements industry. This brain health supplements market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The term "non-invasive brain trauma monitoring devices" refers to devices that aid in monitoring neural and electrical activity and the pressure surrounding the brain. These devices help analyze the blood flow rate in the brain's arteries and veins in cases of brain death, trauma-related brain injury, epilepsy, and other conditions of this nature. The main types of non-invasive brain trauma monitoring devices are the non-invasive intracranial pressure monitor, the non-invasive cerebral edoema dynamic monitor, and others. The non-invasive intracranial pressure monitor refers to a pressure monitor used in the management of various neurological conditions. The non-invasive intracranial pressure monitor is an invasive system with several complications that consists of a ventricular catheter connected to an external strain gauge. The applications of non-invasive brain trauma monitoring devices include cardiology, urology, and nephrology, oncology, gastroenterology, and other applications that are used in hospitals, neurological centers, and by other end users. The global non-invasive brain trauma monitoring devices market is segmented - 1) By Type: Non-invasive Intracranial Pressure Monitor, Non-invasive Cerebral Edema Dynamic Monitor, Other Types 2) By Application: Cardiology, Urology, and Nephrology; Oncology; Gastroenterology; Other Applications 3) By End-User: Hospitals, Neurological Centers, and Other End Users The global non-invasive brain trauma monitoring devices market size is expected to grow from $7.19 billion in 2022 to $7.93 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The non-invasive brain trauma monitoring devices market is expected to grow to $11.55 billion in 2027 at a CAGR of 9.8%. The increased prevalence of neurological disorders and diseases is expected to propel the demand for non-invasive brain trauma monitoring devices. Neurological disorders are one of the major non-communicable diseases (NCDs) that impact people's thoughts, emotions, behavior, and injuries like brain injury, spinal cord injury, or nerve injury. Non-invasive brain trauma monitoring devices help in continuous monitoring and allow physicians to determine the critical level of patients and what actions should be taken to reduce the critical trauma condition of patients. For instance, the World Health Organization (WHO), a Swiss-based health body of the United Nations, estimates that 50 million people worldwide suffered from epilepsy in 2022, with approximately 80% of those individuals residing in low- and middle-income nations. Therefore, the rise in neurological disorders and diseases will drive the market for non-invasive brain trauma monitoring devices. Major players in the non-invasive brain trauma monitoring devices market are Covidien PLC, Hitachi Medical Corporation, Koninklijke Philips N.V., NeuroLogica Corp., NeuroWave Systems Inc., Noraxon U.S.A., RAUMEDIC AG, and Sense Neuro Diagnostics. Technological advancement is a key trend gaining popularity in the non-invasive brain trauma monitoring devices market. Major companies operating in non-invasive brain trauma monitoring devices are developing advanced technologies to strengthen their market position. For instance, in June 2021, FieldLine Inc., a US-based brain imaging manufacturer of quantum sensors, launched the HEDscan system, a wearable, non-invasive magnetoencephalography (MEG) device based on optically pumped magnetometer (OPM) sensor technology. This device generates 3D videos of brain activity by using 128 synchronized quantum magnetic sensors built with FieldLine's microfabrication techniques. In November 2022, SonderMind, a US-based digital behavioral health company, acquired Total Brain for an undisclosed amount. Through this acquisition, SonderMind will help their therapists track treatment results, offer enterprise clients population health reporting, and give insurers and healthcare organizations a complete offering. Total Brain is a US-based company operating in brain monitoring. North America was the largest region in the non-invasive brain trauma monitoring devices market share in 2022. The regions covered in the non-invasive brain trauma monitoring devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the non-invasive brain trauma monitoring devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The non-invasive brain trauma monitoring devices market consists of sales of monitoring devices, consumables, and accessories. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The non-invasive brain trauma monitoring devices market research report is one of a series of new reports from The Business Research Company that provides non-invasive brain trauma monitoring devices market statistics, including non-invasive brain trauma monitoring devices industry global market size, regional shares, competitors with a non-invasive brain trauma monitoring devices market share, detailed non-invasive brain trauma monitoring devices market segments, market trends and opportunities, and any further data you may need to thrive in the non-invasive brain trauma monitoring devices industry. This non-invasive brain trauma monitoring devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Brain monitoring refers to a set of continuous online monitoring, which substantially measures the particle velocity of cerebral blood flow and volume wave in the brain. Brain monitoring is used for individualized patient management such as brain and neuro-related diagnostics and treatment purposes. The main product types in brain monitoring are magnetoencephalography, electroencephalography, cerebral oximeters, functional magnetic resonance imaging (fMRI), intracranial pressure monitoring devices, and others. Magnetoencephalography refers to the noninvasive technique that detects and records the magnetic field associated with electrical activity in the brain. The procedures used are invasive and non-invasive. The applications involved are Parkinson’s disease, traumatic brain injury, epilepsy, dementia, sleep disorders, and others. The various end-users involved are hospitals and clinics, neurology centers, ambulatory surgery centers, diagnostic centers, and others. The global brain monitoring market is segmented - 1) By Product: Magnetoencephalograph, Electroencephalograph, Cerebral Oximeters, Functional Magnetic Resonance Imaging (fMRI), Intracranial Pressure Monitoring Devices, Other Product Types 2) By Procedure: Invasive, Non-invasive 3) By Application: Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Other Applications 4) By End User: Hospitals and Clinics, Neurology Centres, Ambulatory Surgery Centers, Diagnostic Centers, Other End Users The global brain monitoring market size grew from $6.7 billion in 2022 to $7.42 billion in 2023 at a compound annual growth rate (CAGR) of 10.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the brain monitoring is expected to grow to $10.12 billion in 2027 at a CAGR of 8.1%. The increasing incidence and prevalence of neurological disorders are expected to propel the growth of the brain monitoring market going forward. Brain monitoring is defined as the use of instrumentation for the evolution of a neurologic injury. Brain monitoring is used in neurological disorders to provide improved accuracy and reliability of information about the intensity of the neurologic injury. For instance, according to the World Health Organization (WHO) report, the worldwide occurrence of neurological health problems is expected to reach nearly 103 million by the year 2030. Therefore, the rising demand for increasing incidence and prevalence of neurological disorders is driving the growth of the brain monitoring market. Major players in the market are Natus Medical Inc., Nihon Kohden Corporation, Philips Healthcare, GE Healthcare, Compumedics Ltd., Medtronic, Edwards Lifesciences Corporation, Advanced Brain Monitoring, Masimo Corporation, Spiegelberg GmbH & Co. KG, Cadwell Industries, Elekta A.B, Drägerwerk AG & Co. KGaA, and Electrical Geodesics. Technological advancements have emerged as the key trend gaining popularity in the brain monitoring market. Major companies operating in the brain monitoring sector are focused on developing new technological solutions to strengthen their position. For instance, in June 2020, Researchers at the University of Helsinki created an artificial intelligence (AI) technique to analyze viewpoints and draw conclusions based on group brain activity, making testing more efficient and allowing devices to read images straight from the EEG. This infusion has a variety of applications such as clinical diagnostics, soft bioelectronics, wearable devices, and robotics which help the brain monitoring market grow worldwide. In October 2021, Brain Scientific Inc., a Florida-based neurology-focused medical device and software company, merged with Piezo Motion Corp. Through this merger, the company's entire market reach increased, and its capacity to launch novel disruptive products increased. Piezo Motion Corp. is a Florida-based innovator of high-precision motion technology. North America was the largest region in the brain monitoring market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brain monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the brain monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The brain monitoring market includes revenue earned by entities by functional magnetic resonance imaging (FMRI), magnetoencephalography (MEG) and electroencephalography (EEG).The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The brain monitoring market research report is one of a series of new reports from The Business Research Company that provides brain monitoring market statistics, including brain monitoring industry global market size, regional shares, competitors with a brain monitoring market share, detailed brain monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the brain monitoring industry. This brain monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Brain tumor drugs refer to the drugs or medications that are used to treat brain tumor. Chemotherapy, hormone therapies, anticonvulsants, and painkillers are among the drugs used to treat brain tumours. While other prescription drugs are used to manage symptoms while the tumour is being treated, chemotherapy works to reduce or destroy brain tumours. The main types of drugs in brain tumors drugs are temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide is a drug that is intended to treat some types of brain cancer (e.g., glioblastomamultiforme, anaplastic astrocytoma) in individuals who have had tumours return or who have recently been diagnosed with tumours. It’s one of a class of drugs called antineoplastics (cancer medicines). The different types include medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), and others (glioma, acoustic neuroma, meningioma) and are used in various sectors such as hospital pharmacies, clinics, and others. The global brain tumor drugs market is segmented - 1) By Type: Medulloblastoma, Astrocytoma, Oligodendroglioma, Primitive Neuroectodermal (PNET), Others (Glioma, Acoustic Neuroma, Meningioma) 2) By Drugs: Temozolomide, Carmustine, Cisplatin, Bevacizumab, Geftinib, Erlotinib 3) By End User: Hospital Pharmacies, Clinics, Other End-Users The global brain tumor drugs market size will grow from $3.49 billion in 2022 to $3.74 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global brain tumor drugs is expected to grow to $4.74 billion in 2027 at a CAGR of 6.1%. The major driving factor responsible for the growth of the Brain Tumor drugs market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections, and sedentary lifestyles. For example, as per the National Brain Tumor Society, around 700,000 people in the United States around 700,00 people are having a primary brain tumor, and around 86,000 more will be diagnosed. The increasing number of patients with neurological disorders including brain tumor is leading to a rise in the demand for growth of the brain tumor drugs market drugs used in their treatment. Major players in the brain tumor drugs market are Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., AstraZeneca, Carestream Health, Philips Healthcare, Siemens Healthineers, Hitachi Medical Corporation and GE Healthcare. The increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of targeted cancer therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. For example, Everolimus is a targeted therapy that especially blocks cancer cells from growing and spreading. Similarly, Bevacizumab prevents the regeneration of cancer cells, unlike chemical drugs which cannot prevent regeneration. This rising popularity of targeted therapies is expected to affect the sales of conventional chemical Brain Tumor drugs, thus restraining the growth of the brain tumor drugs market during the forecast period. Companies in the brain tumor drugs market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a reduction in the dosage of the drugs, improved shelf life, and reduced toxicity. A few nanodrugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in the treatment of Brain tumors. For instance, Liposomes nanoparticles facilitate easy delivery of drugs to the core cancer cells, these particles if coated with transferrin can even pass through the blood-brain barrier. Companies including GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are adopting this technology to improve the available techniques of medication and treatment. The brain tumor drugs market is governed by regulatory authorities such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The regulatory body requires the companies in the industry to adhere to the same rules for conducting clinical trials, consistently throughout the region. These rules are relating to the transparency of information and maintaining safety standards while conducting clinical trials of newly discovered drugs and therapies throughout the EU. The regulation also encourages cross-border cooperation for making the scope of these clinical tests wider. In December 2021, Sanofi, a France-based pharmaceutical company acquired Amunix Pharmaceuticals Inc. for a deal amount of $1 billion. Through this acquisition, Sanofi’s focus is on developing potentially transformative cancer therapies in immuno-oncology. Amunix Pharmaceuticals Inc. is a US-based pharmaceutical company that also includes brain tumor drugs. North America was the largest region in the brain tumor drugs market in 2022. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the global brain tumor drugs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The brain tumor drugs market consists of sales Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The brain tumor drugs market research report is one of a series of new reports from The Business Research Company that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.